{"paper_id":"3aad23a3-8355-4105-a678-d499f9ef72ca","body_text":"LONG-TERM OUTCOMES OF PHARMACOLOGICAL VERSUS SURGICAL TREATMENT IN WOMEN WITH ENDOMETRIOSIS: IMPACT ON RECURRENCE AND QUALITY OF LIFE — A REVIEW ARTICLE\nDOI:\nhttps://doi.org/10.31435/ijitss.2(50).2026.5080Keywords:\nEndometriosis, Laparoscopic Surgery, Hormonal Therapy, GnRH Antagonists, Progestins, Chronic Pelvic PainAbstract\nBackground: Endometriosis is a chronic inflammatory estrogen-dependent disease affecting approximately 10% of women of reproductive age. Although there have been significant advancements in diagnosis and management, the recurrence and sustained impaired quality of life (QoL) constitute a serious challenge for clinical care. Treatments aim at pharmacological inhibition and surgical excision, but long-term comparative outcomes are controversial.\nObjectives: To assess long-term outcomes of pharmacological versus surgical treatment in endometriosis treatment in women, including recurrence, duration of pain control, quality of life.\nMethods: A systematic review of open-access peer-reviewed studies published from 2006 to 2026 was performed, using PubMed Central, BMC, PLOS and other open-access databases. The inclusion criteria included randomized controlled trials (RCTs), systematic reviews, meta-analyses, and large cohort studies with ≥12 month follow-up. The included studies included were made up of thirty-five eligible studies.\nResults: Surgical treatment is associated with short-term symptom relief and a 5-year recurrence rate of 20–50%. Drug interventions (COCs, progestins, GnRH analogues/antagonists) provide analgesia but have a high recurrence rate on discontinuation. The incidence of the recurrence is markedly decreased as a result of combined postoperative hormonal treatment. QoL is improved in both modalities; sustained benefit associated with recurrence prevention and improved QoL is evident in each modality.\nConclusions: There is no absolute cure for either modality alone. There is an indication for personalized interventions with treatment and individualized approach, surgical and long-term hormonal suppression leading to the most durable results in patients.\nReferences\nAlonso, A., Gunther, K., Maheux-Lacroix, S., & Abbott, J. (2024). Medical management of endometriosis. Current Opinion in Obstetrics & Gynecology, 36(5), 353–361. https://doi.org/10.1097/GCO.0000000000000983\nArcoverde, F. V. L., Andres, M. P., Borrelli, G. M., Barbosa, P. A., Simões Abrão, M., & Kho, R. M. (2019). Surgery for endometriosis improves major domains of quality of life: A systematic review and meta-analysis. Journal of Minimally Invasive Gynecology, 26(2), 266–278. https://doi.org/10.1016/j.jmig.2018.09.774\nAs-Sanie, S., Harris, R. E., Harte, S. E., Tu, F. F., Neshewat, G., & Clauw, D. J. (2013). Increased pressure pain sensitivity in women with chronic pelvic pain. Obstetrics & Gynecology, 122(5), 1047–1055. https://doi.org/10.1097/AOG.0b013e3182a7e1f5\nBedaiwy, M. A., Allaire, C., & Alfaraj, S. (2017). Long-term medical management of endometriosis with dienogest and with a GnRH agonist and add-back therapy. Fertility and Sterility, 107(3), 537–548. https://doi.org/10.1016/j.fertnstert.2016.12.024\nBrown, J., Crawford, T. J., Allen, C., & Hopewell, S. (2017). Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database of Systematic Reviews, 2017(1), Article CD004753. https://doi.org/10.1002/14651858.CD004753.pub4\nBrown, J., Pan, A., & Hart, R. J. (2010). Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database of Systematic Reviews, 2010(12), Article CD008475. https://doi.org/10.1002/14651858.CD008475.pub2\nBulun, S. E., Yilmaz, B. D., Sison, C., Miyazaki, K., Bernardi, L., Liu, S., Kohlmeier, A., Yin, P., Milad, M., & Wei, J. (2019). Endometriosis. Endocrine Reviews, 40(4), 1048–1079. https://doi.org/10.1210/er.2018-00242\nCooper, K. G., Bhattacharya, S., Daniels, J. P., Cheed, V., Gennard, L., Leighton, L., Pirie, D., et al. (2024). Preventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: The PRE-EMPT RCT. Science Quarterly, 28(55), 1–77. https://doi.org/10.3310/SQWY6998\nDe Graaff, A. A., D’Hooghe, T. M., Dunselman, G. A. J., Dirksen, C. D., Hummelshoj, L., & Simoens, S. (2013). The significant effect of endometriosis on physical, mental and social wellbeing. Human Reproduction, 28(10), 2677–2685. https://doi.org/10.1093/humrep/det284\nDuffy, J. M. N., Arambage, K., Correa, F. J. S., Olive, D., Farquhar, C., Garry, R., & Barlow, D. H. (2020). Laparoscopic surgery for endometriosis. Cochrane Database of Systematic Reviews, 2020(4), Article CD011031. https://doi.org/10.1002/14651858.CD011031.pub3\nFerrari, S. M., Dolci, C., Tandoi, I., Schimberni, M., Bartiromo, L., Salmeri, N., D’Alessandro, S., Carnemolla, G., Grisafi, G., & Candiani, M. (2025). Long-term postoperative recurrence rates and fertility outcomes after endometrioma CO₂-laser vaporization: A five-year follow-up experience. Journal of Minimally Invasive Gynecology, 32(2), 171–176. https://doi.org/10.1016/j.jmig.2024.09.367\nHoldsworth-Carson, S. J., Chung, J., Machalek, D. A., Li, R., Jun, B. K., Griffiths, M. J., Churchill, M., et al. (2024). Predicting disease recurrence in patients with endometriosis: An observational study. BMC Medicine, 22, Article 320. https://doi.org/10.1186/s12916-024-03508-7\nKwok, H., Li, J., Li, X., Jiang, H., Li, T., & Chen, S. (2025). Risk factors for postoperative recurrence of deep infiltrating endometriosis during a 6- to 12-year follow-up. Scientific Reports, 15, Article 37544. https://doi.org/10.1038/s41598-025-21821-w\nLee, S. R., Yi, K. W., Song, J. Y., Seo, S. K., Lee, D.-Y., Cho, S., Kim, S. H., et al. (2018). Efficacy and safety of long-term use of dienogest in women with ovarian endometrioma. Reproductive Sciences, 25(3), 341–346. https://doi.org/10.1177/1933719117725820\nMcDonnell, R., Gollow, J., Nathan, E., Doherty, D., Majumder, K., Wilkinson, E., McElhinney, B., Karthigasu, K., & Hart, R. (2025). Endometriosis quality of life cohort study: Long-term impact of radical laparoscopic excision of endometriosis. Gynecology and Minimally Invasive Therapy, 14(1), 57–65. https://doi.org/10.4103/gmit.gmit_156_23\nMuzii, L., Di Tucci, C., Galati, G., Carbone, F., Palaia, I., Bogani, G., … Tomao, F. (2023). The efficacy of dienogest in reducing disease and pain recurrence after endometriosis surgery: A systematic review and meta-analysis. Reproductive Sciences, 30(11), 3135–3143. https://doi.org/10.1007/s43032-023-01266-0\nOsuga, Y., Seki, Y., Tanimoto, M., Kusumoto, T., Kudou, K., & Terakawa, N. (2021). Relugolix, an oral GnRH receptor antagonist, in women with endometriosis-associated pain: Phase 2 safety and efficacy 24-week results. BMC Women’s Health, 21, Article 393. https://doi.org/10.1186/s12905-021-01393-3\nOthman, E. R., Al-Hendy, A., Mostafa, R., Lambalk, C. B., & Mijatovic, V. (2024). Oral GnRH antagonists in combination with estradiol and norethindrone acetate for pain relief associated with endometriosis: A review of evidence of a novel class of hormonal agents. International Journal of Women’s Health, 16, 309–321. https://doi.org/10.2147/IJWH.S442357\nRoman, H., Huet, E., Bridoux, V., Khalil, H., Hennetier, C., Bubenheim, M., … Tuech, J.-J. (2022). Long-term outcomes following surgical management of rectal endometriosis: Seven-year follow-up of patients enrolled in a randomized trial. Journal of Minimally Invasive Gynecology, 29(6), 767–775. https://doi.org/10.1016/j.jmig.2022.02.007\nRömer, T. (2018). Long-term treatment of endometriosis with dienogest: Retrospective analysis of efficacy and safety in clinical practice. Archives of Gynecology and Obstetrics, 298(4), 747–753. https://doi.org/10.1007/s00404-018-4864-8\nSallam, H. N., Garcia-Velasco, J. A., Dias, S., & Arici, A. (2006). Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database of Systematic Reviews, 2006(1), Article CD004635. https://doi.org/10.1002/14651858.CD004635.pub2\nSchindler, A. E. (2011). Dienogest in long-term treatment of endometriosis. International Journal of Women’s Health, 3, 175–184. https://doi.org/10.2147/IJWH.S5633\nSeo, J.-W., Lee, D.-Y., Kim, S. E., Yoon, B. K., & Choi, D. (2019). Comparison of long-term use of combined oral contraceptive after gonadotropin-releasing hormone (GnRH) agonist plus add-back therapy versus dienogest to prevent recurrence of ovarian endometrioma after surgery. European Journal of Obstetrics & Gynecology and Reproductive Biology, 236, 53–57. https://doi.org/10.1016/j.ejogrb.2019.02.032\nSeracchioli, R., Mabrouk, M., Manuzzi, L., Vicenzi, C., Frascà, C., Elmakky, A., & Venturoli, S. (2009). Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis. Human Reproduction, 24(11), 2729–2735. https://doi.org/10.1093/humrep/dep259\nTaylor, H. S., Giudice, L. C., Lessey, B. A., et al. (2017). Treatment of endometriosis-associated pain with elagolix. New England Journal of Medicine, 377, 28–40. https://doi.org/10.1056/NEJMoa1700089\nWenzl, A., Wenzl, R., Gstoettner, M., Kuessel, L., Husslein, H., Heine, J., Sandrieser, L., Bekos, C., & Perricos-Hess, A. (2024). Long-term follow-up of the quality of life of endometriosis patients after surgery: A comparative study. Journal of Clinical Medicine, 13(18), Article 5641. https://doi.org/10.3390/jcm13185641\nWu, H., Liu, J.-J., Ye, S.-T., Liu, J., & Li, N. (2024). Efficacy and safety of dienogest in the treatment of deep infiltrating endometriosis: A meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 308, 69–78. https://doi.org/10.1016/j.ejogrb.2024.03.032\nZakhari, A., Delpero, E., McKeown, S., Tomlinson, G., Bougie, O., & Murji, A. (2020). Endometriosis recurrence following post-operative hormonal suppression: A systematic review and meta-analysis. Human Reproduction Update, 27(1), 96–107. https://doi.org/10.1093/humupd/dmaa033\nDownloads\nPublished\nIssue\nSection\nLicense\nCopyright (c) 2026 Urszula Marzec, Agnieszka Giza, Eliza Rajca, Aleksandra Cyrkler, Natalia Cieślak, Paulina Giza, Agata Chodkowska, Kamila Czyżak, Karol Dąbek, Karolina Wymoczył\nThis work is licensed under a Creative Commons Attribution 4.0 International License.\nAll articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.\nCC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.","source_license":"CC0","license_restricted":false}